المؤلفون: Encinas, Cristina, Hernandez-Rivas, José-Ãngel, Oriol, Albert, Rosiñol, Laura, Blanchard, María Jesús, Bellón, José-María, García-Sanz, Ramón, de la Rubia, Javier, López de la Guía, Ana, Jímenez-Ubieto, Ana, Jarque, Isidro, Iñigo, Belén, Dourdil, Victoria, De Arriba, Felipe, Cuéllar Pérez-Ãvila, Clara, Gonzalez, Yolanda, Hernández, Miguel-Teodoro, Bargay, Joan, Granell, Miquel, Rodríguez-Otero, Paula, Silvent, Maialen, Cabrera, Carmen, Rios, Rafael, Alegre, Adrián, Gironella, Mercedes, Gonzalez, Marta-Sonia, Sureda, Anna, Sampol, Antonia, Ocio, Enrique M., Krsnik, Isabel, García, Antonio, García-Mateo, Aránzazu, Soler, Joan-Alfons, Martín Sánchez, Jesús, Arguiñano, José M, Mateos, M. V., Bladé Creixenti, Juan, San-Miguel, J, Lahuerta, J. J, Martínez-López, Joaquín

مصطلحات موضوعية: Antibiotic Prophylaxis, Humans, Male, Multiple Myeloma

الوصف: Altres ajuts: PETHEMA (Spanish Program for the Treatment of Hematological Diseases), Madrid, Spain ; Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin ≤30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0-2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.

وصف الملف: application/pdf

العلاقة: Blood Cancer Journal; Vol. 12 Núm. 4 (april 2022), p. 68; https://ddd.uab.cat/record/280855Test; urn:10.1038/s41408-022-00652-2; urn:oai:ddd.uab.cat:280855; urn:scopus_id:85128796138; urn:articleid:20445385v12n4p68; urn:pmid:35440057; urn:pmc-uid:9018751; urn:pmcid:PMC9018751; urn:oai:pubmedcentral.nih.gov:9018751

الإتاحة: https://ddd.uab.cat/record/280855Test

المؤلفون: Mosquera Orgueira, Adrian, González Pérez, Marta Sonia, Diaz Arias, José, Rosiñol, Laura, Oriol, Albert, Teruel, Ana Isabel, Martínez-López, Joaquín, Palomera, Luis, Granell, Miquel, Blanchard, María Jesús, de la Rubia, Javier, López de la Guia, Ana, Ríos-Tamayo, Rafael, Sureda, Anna, Hernández, Miguel Teodoro, Bengoechea, Enrique, Calasanz, M.J, Gutierrez, Norma, Martin, María Luís, Bladé Creixenti, Juan, Lahuerta, J. J, San-Miguel, J, Mateos, M. V, Universitat Autònoma de Barcelona

مصطلحات موضوعية: Humans, Multiple Myeloma, Neoplasm Staging, Prognosis, Risk Assessment, Unsupervised Machine Learning

وصف الملف: application/pdf

العلاقة: Blood Cancer Journal; Vol. 12 Núm. 4 (april 2022), p. 76; https://ddd.uab.cat/record/270545Test; urn:10.1038/s41408-022-00647-z; urn:oai:ddd.uab.cat:270545; urn:scopus_id:85128861737; urn:articleid:20445385v12n4p76; urn:pmid:35468898; urn:pmc-uid:9038663; urn:pmcid:PMC9038663; urn:oai:pubmedcentral.nih.gov:9038663

الإتاحة: https://ddd.uab.cat/record/270545Test

المؤلفون: Puig, Noemí, Contreras, María-Teresa, Agulló, Cristina, Martínez-López, Joaquín, Oriol, Albert, Blanchard, María-Jesús, Ríos, Rafael, Martín, Jesús, Iñigo, María-Belén, Sureda, Anna, Hernández, Miguel-Teodoro, de la Rubia, Javier, González-Calle, Verónica, Krsnik, Isabel, Cabañas, Valentín, Palomera, Luis, Moraleda, José-María, Bargay, Joan, Cedena, María-Teresa, Paiva, Bruno, Rosiñol, Laura, Bladé, Joan, San Miguel, Jesús, Lahuerta, Juan-José, Mateos, María-Victoria

مصطلحات موضوعية: Antibodies, Monoclonal, Hematopoietic Stem Cell Transplantation, Humans, Immunoglobulin Light Chains, Mass Spectrometry, Multiple Myeloma, Transplantation, Autologous

الوصف: Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), and after induction (n = 183), autologous stem cell transplantation (n = 173), and consolidation (n = 173). At baseline, the isotypes identified with both methods fully matched in 82.1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in >80% of cases, being most discordances due to EXENT&FLC-MS+ but IFE- cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE- patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P = .0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients' outcome. This trial was registered at www.clinicaltrials.gov as #NCT01916252.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/20250Test; PMC9198943; https://doi.org/10.1182/bloodadvances.2021006762Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198943/pdfTest

الإتاحة: https://doi.org/10.1182/bloodadvances.2021006762Test
http://hdl.handle.net/10668/20250Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198943/pdfTest

المؤلفون: Ríos-Tamayo, Rafael, Soler, Juan Alfons, García-Sánchez, Ricarda, Pérez Persona, Ernesto, Arnao, Mario, García-Guiñón, Antoni, Domingo, Abel, González-Pardo, Miriam, de la Rubia, Javier, Mateos, María Victoria

المصدر: Hematology; Dec2023, Vol. 28 Issue 1, p1-11, 11p

مصطلحات موضوعية: MULTIPLE myeloma, MONOCLONAL antibodies, CLINICAL trials, PROGRESSION-free survival

مستخلص: To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives. This was an observational, multicenter, ambispective study of RRMM treated with or without a mAb. A total of 171 patients were included. For the group treated without mAb, the median (95% CI) progression-free survival (PFS) to relapse was 22.4 (17.8-27.0) months; partial response or better (≥PR) and complete response or better (≥CR) was observed in 74.1% and 24.1% of patients, respectively; and median time to first response in first relapse was 2.0 months and in second relapse was 2.5 months. For the group of patients treated with mAb in first or second relapse, the median PFS was 20.9 (95% CI, could not be evaluated) months; the ≥ PR and ≥ CR rates were 76,2% and 28.6%, respectively; and the median time to first response in first relapse was 1.2 month and in second relapse was 1.0 months. The safety profiles for the combinations were consistent with those expected. The incorporation of mAb in RW practice for the treatment of RRMM has shown good quality and speed of response with a similar safety profile shown in randomized clinical trials. [ABSTRACT FROM AUTHOR]

: Copyright of Hematology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Cárdenas, María C., García-Sanz, Ramón, Puig, Noemí, Pérez-Surribas, David, Flores-Montero, Juan, Ortiz-Espejo, María, de la Rubia, Javier, Cruz-Iglesias, Elena

المصدر: Clinical Chemistry & Laboratory Medicine; Nov2023, Vol. 61 Issue 12, p2115-2130, 16p

مصطلحات موضوعية: MONOCLONAL gammopathies, MONOCLONAL antibodies, IMMUNOGLOBULIN light chains, BONE marrow examination, BLOOD transfusion, HEMATOLOGY

مستخلص: Monoclonal gammopathies (MG) are characterized by the proliferation of plasma cells that produce identical abnormal immunoglobulins (intact or some of their subunits). This abnormal immunoglobulin component is called monoclonal protein (M-protein), and is considered a biomarker of proliferative activity. The identification, characterization and measurement of M-protein is essential for the management of MG. We conducted a systematic review of the different tests and measurement methods used in the clinical laboratory for the study of M-protein in serum and urine, the biochemistry and hematology tests necessary for clinical evaluation, and studies in bone marrow, peripheral blood and other tissues. This review included literature published between 2009 and 2022. The paper discusses the main methodological characteristics and limitations, as well as the purpose and clinical value of the different tests used in the diagnosis, prognosis, monitoring and assessment of treatment response in MG. Included are methods for the study of M-protein, namely electrophoresis, measurement of immunoglobulin levels, serum free light chains, immunoglobulin heavy chain/light chain pairs, and mass spectrometry, and for the bone marrow examination, morphological analysis, cytogenetics, molecular techniques, and multiparameter flow cytometry. [ABSTRACT FROM AUTHOR]

: Copyright of Clinical Chemistry & Laboratory Medicine is the property of De Gruyter and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Cárdenas, María C., García-Sanz, Ramón, Puig, Noemí, Pérez-Surribas, David, Flores-Montero, Juan, Ortiz-Espejo, María, De la Rubia, Javier, Cruz-Iglesias, Elena

المصدر: Clinical Chemistry & Laboratory Medicine; Nov2023, Vol. 61 Issue 12, p2131-2142, 12p

مصطلحات موضوعية: MONOCLONAL gammopathies, BLOOD transfusion, PATHOLOGICAL laboratories, CLINICAL pathology, HEMATOLOGY, MONOCLONAL antibodies

مستخلص: Monoclonal gammopathies (MG) are a group of clinical entities characterized by the clonal expansion of monoclonal immunoglobulin (M-protein) secreting plasma cells (PC). This document presents the consensus recommendations of the Spanish Society of Laboratory Medicine (SEQC^ML) and the Spanish Society of Hematology and Hemotherapy (SEHH) for the study of MG. The recommendations were established based on scientific evidence and the opinion of experts in MG from the clinical laboratory and clinical hematology fields. Recommendations are proposed for the diagnosis of MG and for patient follow-up according to the type of MG and whether or not the patient is undergoing treatment, and to monitor the disease stability, response to therapy and disease progression. With respect to the diagnosis, we describe the most recent criteria and classification established by the International Myeloma Working Group (IMWG) for multiple myeloma (MM), smoldering MM, monoclonal gammopathy of undermined significance (MGUS) and other related entities. Indications are given about the analytical requirements and application of the different serum and urine laboratory tests (study, detection, identification and measurement of M-protein) and the bone marrow study. Recommendations on the clinical laboratory results report model are established to harmonize and ensure that all relevant information is available, including its content, expression, and interpretive comments. [ABSTRACT FROM AUTHOR]

: Copyright of Clinical Chemistry & Laboratory Medicine is the property of De Gruyter and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Puig, Noemi, Hernández, Miguel T, Rosiñol, Laura, González, Esther, de Arriba, Felipe, Oriol, Albert, González-Calle, Verónica, Escalante, Fernando, de la Rubia, Javier, Gironella, Mercedes, Ríos, Rafael, García-Sánchez, Ricarda, Arguiñano, José M, Alegre, Adrián, Martín, Jesús, Gutiérrez, Norma C, Calasanz, María J, Martín, María L, Couto, María Del Carmen, Casanova, María, Arnao, Mario, Pérez-Persona, Ernesto, Garzón, Sebastián, González, Marta S, Martín-Sánchez, Guillermo, Ocio, Enrique M, Coleman, Morton, Encinas, Cristina, Vale, Ana M, Teruel, Ana I, Cortés-Rodríguez, María, Paiva, Bruno, Cedena, M Teresa, San-Miguel, Jesús F, Lahuerta, Juan J, Bladé, Joan, Niesvizky, Ruben, Mateos, María-Victoria

مصطلحات موضوعية: Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Clarithromycin, Dexamethasone, Female, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Male, Multiple Myeloma, Transplantation, Autologous, Treatment Outcome

الوصف: Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 patients with MM ineligible for ASCT received Rd with or without clarithromycin until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). With a median follow-up of 19 months (range, 0-54), no significant differences in the median PFS were observed between the two arms (C-Rd 23 months, Rd 29 months; HR 0.783, p = 0.14), despite a higher rate of complete response (CR) or better in the C-Rd group (22.6% vs 14.4%, p = 0.048). The most common G3-4 adverse events were neutropenia [12% vs 19%] and infections [30% vs 25%], similar between the two arms; however, the percentage of toxic deaths was higher in the C-Rd group (36/50 [72%] vs 22/40 [55%], p = 0.09). The addition of clarithromycin to Rd in untreated transplant ineligible MM patients does not improve PFS despite increasing the ≥CR rate due to the higher number of toxic deaths in the C-Rd arm. Side effects related to overexposure to steroids due to its delayed clearance induced by clarithromycin in this elderly population could explain these results. The trial was registered in clinicaltrials.gov with the name GEM-CLARIDEX: Ld vs BiRd and with the following identifier NCT02575144. The full trial protocol can be accessed from ClinicalTrials.gov. This study received financial support from BMS/Celgene.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/17818Test; PMC8139975; https://www.nature.com/articles/s41408-021-00490-8.pdfTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139975/pdfTest

الإتاحة: https://doi.org/10.1038/s41408-021-00490-8Test
http://hdl.handle.net/10668/17818Test
https://www.nature.com/articles/s41408-021-00490-8.pdfTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139975/pdfTest

المؤلفون: Perez, Cristina, Botta, Cirino, Zabaleta, Aintzane, Puig, Noemi, Cedena, Maria-Teresa, Goicoechea, Ibai, Alameda, Daniel, San José-Eneriz, Edurne, Merino, Juana, Rodríguez-Otero, Paula, Maia, Catarina, Alignani, Diego, Maiso, Patricia, Manrique, Irene, Lara-Astiaso, David, Vilas-Zornoza, Amaia, Sarvide, Sarai, Riillo, Caterina, Rossi, Marco, Rosiñol, Laura, Oriol, Albert, Blanchard, María-Jesús, Rios, Rafael, Sureda, Anna, Martin, Jesus, Martinez, Rafael, Bargay, Joan, de la Rubia, Javier, Hernandez, Miguel-Teodoro, Martinez-Lopez, Joaquin, Orfao, Alberto, Agirre, Xabier, Prosper, Felipe, Mateos, Maria-Victoria, Lahuerta, Juan-José, Blade, Joan, San-Miguel, Jesús F, Paiva, Bruno

مصطلحات موضوعية: Antigens, CD, Female, Follow-Up Studies, Humans, Lymphocyte Count, Male, Middle Aged, Multiple Myeloma, Myeloid-Derived Suppressor Cells, Neoplasm Proteins, Neutrophils, T-Lymphocytes, Transcription, Genetic

الوصف: Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to provide the phenotypic profile of G-MDSCs based on their prognostic significance in MM, immunosuppressive potential, and molecular program. The preestablished phenotype of G-MDSCs was evaluated in bone marrow samples from controls and MM patients using multidimensional flow cytometry; surprisingly, we found that CD11b+CD14-CD15+CD33+HLADR- cells overlapped with common eosinophils and neutrophils, which were not expanded in MM patients. Therefore, we relied on automated clustering to unbiasedly identify all granulocytic subsets in the tumor microenvironment: basophils, eosinophils, and immature, intermediate, and mature neutrophils. In a series of 267 newly diagnosed MM patients (GEM2012MENOS65 trial), only the frequency of mature neutrophils at diagnosis was significantly associated with patient outcome, and a high mature neutrophil/T-cell ratio resulted in inferior progression-free survival (P

العلاقة: http://hdl.handle.net/10668/15418Test; https://ashpublications.org/blood/article-pdf/136/2/199/1747998/bloodbld2019004537.pdfTest

الإتاحة: https://doi.org/10.1182/blood.2019004537Test
http://hdl.handle.net/10668/15418Test
https://ashpublications.org/blood/article-pdf/136/2/199/1747998/bloodbld2019004537.pdfTest

المؤلفون: Termini, Rosalinda, Zihala, David, Terpos, Evangelos, Perez-Montana, Albert, Jelinek, Tomas, Raab, Marc, Weinhold, Niels, Mai, Elias K, Grab, Anna Luise, Corre, Jill, Vergez, Francois, Sacco, Antonio, Chiarini, Marco, Giustini, Viviana, Tucci, Alessandra, Rodriguez, Sara, Moreno, Cristina, Perez, Cristina, Maia, Catarina, Martin-Sanchez, Esperanza, Guerrero, Camila, Botta, Cirino, Garces, Juan-Jose, Lopez, Aitziber, Tamariz-Amador, Luis-Esteban, Prosper, Felipe, Bargay, Joan, Cabezudo, Maria-Elena, Ocio, Enrique M, Hajek, Roman, Martinez-Lopez, Joaquin, Solano, Fernando, Iglesias, Rebeca, Paiva, Artur, Geraldes, Catarina, Matos Silva, Helena, Gomez, Clara, De Arriba, Felipe, Ludwig, Heinz, Garcia-Guinon, Antoni, Casanova, Maria, Alegre, Adrian, Cabanas, Valentin, Sirvent, Maialen, Oriol, Albert, de la Rubia, Javier, Hernandez-Rivas, Jose-Angel, Palomera, Luis, Sarasa, Maria, Rios, Pablo, Puig, Noemi, Mateos, Maria-Victoria, Flores-Montero, Juan, Orfao, Alberto, Goldschmidt, Hartmut, Avet-Loiseau, Herve, Roccaro, Aldo M, San-Miguel, Jesus F, Paiva, Bruno

المساهمون: Termini, Rosalinda, Zihala, David, Terpos, Evangelo, Pérez-Montaña, Albert, Jelinek, Toma, Raab, Marc, Weinhold, Niel, Mai, Elias K, Grab, Anna Luise, Corre, Jill, Vergez, Francoi, Sacco, Antonio, Chiarini, Marco, Giustini, Viviana, Tucci, Alessandra, Rodríguez, Sara, Moreno, Cristina, Perez, Cristina, Maia, Catarina, Martin-Sanchez, Esperanza, Guerrero, Camila, Botta, Cirino, Garcés, Juan-Jose, Lopez, Aitziber, Tamariz-Amador, Luis-Esteban, Prósper, Felipe, Bargay, Joan, Cabezudo, Maria-Elena, Ocio, Enrique M, Hájek, Roman, Martinez-Lopez, Joaquin, Solano, Fernando, Iglesias, Rebeca, Paiva, Artur, Geraldes, Catarina, Matos Silva, Helena, Gomez, Clara, De Arriba, Felipe, Ludwig, Heinz, Garcia-Guiñon, Antoni, Casanova, Maria, Alegre, Adrian, Cabañas, Valentin, Sirvent, Maialen, Oriol, Albert, De la Rubia, Javier, Hernández-Rivas, José-Ángel, Palomera, Lui, Sarasa, Maria, Rios, Pablo, Puig, Noemi, Mateos, Maria-Victoria, Flores-Montero, Juan, Orfao, Alberto, Goldschmidt, Hartmut, Avet-Loiseau, Herve, Roccaro, Aldo M, San-Miguel, Jesus F, Paiva, Bruno

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

مصطلحات موضوعية: Smoldering Multiple Myeloma, Cancer Research, myeloma, Oncology, Disease Progression, Humans, Immunoglobulin Light Chains, Prognosis, Multiple Myeloma, Risk Assessment, circulating tumor cell, immune profile

الوصف: Purpose: Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under- and overtreatment. We hypothesized that replacing bone marrow (BM) plasma cells (PC) for circulating tumor cells (CTC), and adding immune biomarkers in peripheral blood (PB) for the identification of patients at risk of progression due to lost immune surveillance, could improve the International Myeloma Working Group 20/2/20 model. Experimental Design: We report the outcomes of 150 patients with SMM enrolled in the iMMunocell study, in which serial assessment of tumor and immune cells in PB was performed every 6 months for a period of 3 years since enrollment. Results: Patients with >0.015% versus ≤0.015% CTCs at baseline had a median time-to-progression of 17 months versus not reached (HR, 4.9; P 20% BM PCs had no prognostic value in a multivariate analysis that included serum free light-chain ratio >20, >2 g/dL M-protein, and >0.015% CTCs. The 20/2/20 and 20/2/0.015 models yielded similar risk stratification (C-index of 0.76 and 0.78). The combination of the 20/2/0.015 model with an immune risk score based on the percentages of SLAN+ and SLAN− nonclassical monocytes, CD69+HLADR+ cytotoxic NK cells, and CD4+CXCR3+ stem central memory T cells, allowed patient’ stratification into low, intermediate-low, intermediate-high, and high-risk disease with 0%, 20%, 39%, and 73% rates of progression at 2 years. Conclusions: This study showed that CTCs outperform BM PCs for assessing tumor burden. Additional analysis in larger series are needed to define a consensus cutoff of CTCs for minimally invasive stratification of SMM.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff52cdd72f2b776b5805e7e201bfa32Test
http://hdl.handle.net/10261/296559Test

المؤلفون: Paiva, Bruno, Puig, Noemi, Cedena, Maria-Teresa, Rosiñol, Laura, Cordón, Lourdes, Vidriales, María-Belén, Burgos, Leire, Flores-Montero, Juan, Sanoja-Flores, Luzalba, Lopez-Anglada, Lucia, Maldonado, Roberto, de la Cruz, Javier, Gutierrez, Norma C, Calasanz, Maria-Jose, Martin-Ramos, Maria-Luisa, Garcia-Sanz, Ramón, Martinez-Lopez, Joaquin, Oriol, Albert, Blanchard, María-Jesús, Rios, Rafael, Martin, Jesus, Martinez-Martinez, Rafael, Sureda, Anna, Hernandez, Miguel-Teodoro, de la Rubia, Javier, Krsnik, Isabel, Moraleda, Jose-Maria, Palomera, Luis, Bargay, Joan, Van Dongen, Jacques J M, Orfao, Alberto, Mateos, Maria-Victoria, Blade, Joan, San-Miguel, Jesús F, Lahuerta, Juan-José, GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group

مصطلحات موضوعية: Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Clinical Trials, Phase III as Topic, Dexamethasone, Female, Flow Cytometry, Humans, Lenalidomide, Longitudinal Studies, Male, Middle Aged, Multiple Myeloma, Neoplasm, Residual, Randomized Controlled Trials as Topic

الوصف: Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG). In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), autologous transplantation, and two consolidation courses with VRD. MRD was assessed in 1,100 bone marrow samples from 397 patients; the 61 patients without MRD data discontinued treatment during induction and were considered MRD positive for intent-to-treat analysis. The median limit of detection achieved by NGF was 2.9 × 10-6. Patients received maintenance (lenalidomide ± ixazomib) according to the companion PETHEMA/GEM2014MAIN trial. Overall, 205 (45%) of 458 patients had undetectable MRD after consolidation, and only 14 of them (7%) have experienced progression thus far; seven of these 14 displayed extraosseous plasmacytomas at diagnosis and/or relapse. Using time-dependent analysis, patients with undetectable MRD had an 82% reduction in the risk of progression or death (hazard ratio, 0.18; 95% CI, 0.11 to 0.30; P The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate treatment efficacy in MM.

العلاقة: http://hdl.handle.net/10668/14743Test

الإتاحة: https://doi.org/10.1200/JCO.19.01231Test
http://hdl.handle.net/10668/14743Test